Literature DB >> 15902690

Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART).

François-Jérôme Authier1, Patrick Chariot, Romain K Gherardi.   

Abstract

Skeletal muscle involvement can occur at all stages of human immunodeficiency virus (HIV) infection, and may represent the first manifestation of the disease. Myopathies in HIV-infected patients are classified as follows: (1) HIV-associated myopathies and related conditions, including HIV polymyositis, inclusion-body myositis, nemaline myopathy, diffuse infiltrative lymphocytosis syndrome (DILS), HIV-wasting syndrome, vasculitic processes, myasthenic syndromes, and chronic fatigue; (2) muscle complications of antiretroviral therapy, including zidovudine and toxic mitochondrial myopathies related to other nucleoside-analogue reverse-transcriptase inhibitors (NRTIs), HIV-associated lipodystrophy syndrome, and immune restoration syndrome related to highly active antiretroviral therapy (HAART); (3) opportunistic infections and tumor infiltrations of skeletal muscle; and (4) rhabdomyolysis. Introduction of HAART has dramatically modified the natural history of HIV disease by controlling viral replication, but, in turn, lengthening of the survival of HIV-infected individuals has been associated with an increasing prevalence of iatrogenic conditions.

Entities:  

Mesh:

Year:  2005        PMID: 15902690     DOI: 10.1002/mus.20338

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  26 in total

1.  Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study.

Authors:  P Vivithanaporn; G Heo; J Gamble; H B Krentz; A Hoke; M J Gill; C Power
Journal:  Neurology       Date:  2010-08-25       Impact factor: 9.910

Review 2.  [Medically induced myopathia].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

3.  Fatigue-related gene networks identified in CD(14)+ cells isolated from HIV-infected patients: part I: research findings.

Authors:  Joachim G Voss; Adrian Dobra; Caryn Morse; Joseph A Kovacs; Robert L Danner; Peter J Munson; Carolea Logan; Zoila Rangel; Joseph W Adelsberger; Mary McLaughlin; Larry D Adams; Raghavan Raju; Marinos C Dalakas
Journal:  Biol Res Nurs       Date:  2013-01-16       Impact factor: 2.522

4.  Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study.

Authors:  Clara Y Jones; Camille A Jones; Ira B Wilson; Tamsin A Knox; Andrew S Levey; Donna Spiegelman; Sherwood L Gorbach; Frederick Van Lente; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2008-05-02       Impact factor: 8.860

5.  External ophthalmoplegia in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

Authors:  Stacy L Pineles; Joseph L Demer; Gary N Holland; Susan S Ransome; Laura Bonelli; Federico G Velez
Journal:  J AAPOS       Date:  2012-11-14       Impact factor: 1.220

Review 6.  Human immunodeficiency virus-associated obstructive lung diseases.

Authors:  Matthew R Gingo; Alison Morris; Kristina Crothers
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 7.  Antiretroviral therapy and central nervous system HIV type 1 infection.

Authors:  Richard W Price; Serena Spudich
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

Review 8.  [Highly active antiretroviral therapy of neuro-AIDS. Side effects on the nervous system and interactions].

Authors:  I W Husstedt; D Reichelt; E Neuen-Jakob; K Hahn; F Kästner; R von Einsiedel; B Vielhaber; G Arendt; S Evers
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

9.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20

10.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.